FASN and colonic neoplasm: Specifically, de novo lipogenesis is a requirement of cancer cells and targeting fatty acid synthase (FASN) using the TVB-2640 FASN inhibitor is nowadays in phase I or II clinical trials for breast, lung and colon cancers [13].